ClinicalTrials.gg
RecruitingNCT07554287GDMUpdated Jun 18, 2026

Effects of Leg Ergometer Versus Arm Ergometer on Blood Glucose, Exercise Tolerance, Weight, and Psychological Stress Among Gestational Diabetic Patients

An interventional study of Leg Ergometer and Arm Ergometer in Diabetes During Pregnancy, Pregnancy Complications and Pregnancy in Diabetes, sponsored by Lahore University of Biological and Applied Sciences. Recruiting at 1 site in Pakistan. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Lahore University of Biological and Applied Sciences · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The current study is a single-blind, parallel-group randomized controlled trial involving 108 participants with diabetes during pregnancy. The trial will compare leg ergometer with arm ergometer. Interventions will be delivered three times per week for eight weeks. The primary outcomes are glucose, exercise tolerance, weight, and psychological stress. Assessments will be conducted at baseline and after eight weeks. The trial will be carried out at Jinnah hospital, Services hospital, Sir Ganga Ram Hospital, Lahore. The hypothesis is that the leg ergometer including aerobic exercise will result in greater reduction in glucose and exercise tolerance, weight and stress management than arm ergometer.

Read the detailed description

Gestational diabetes mellitus (GDM) is a common metabolic condition during pregnancy, characterized by glucose intolerance and increased insulin resistance. It is associated with adverse maternal and fetal outcomes, including excessive gestational weight gain, reduced exercise tolerance, and increased psychological stress. Non-pharmacological interventions, particularly structured exercise programs, are recommended as first-line management to improve glycemic control and overall maternal health.

Aerobic exercise enhances glucose uptake through skeletal muscle activity and improves insulin sensitivity. Ergometer-based exercise provides a safe, controlled, and feasible method of delivering aerobic training during pregnancy. However, there is limited evidence comparing different exercise modalities, particularly leg versus arm ergometer, in women with gestational diabetes.

This study is a randomized, parallel-group controlled trial designed to compare the effects of leg ergometer exercise and arm ergometer exercise, both combined with standard care, in women with gestational diabetes during the second trimester. A total of eligible participants will be randomly assigned into two groups. The experimental group will perform leg ergometer exercise, while the comparison group will perform arm ergometer exercise. Both interventions will be supervised, conducted three times per week for eight weeks, with each session lasting 20-30 minutes at moderate intensity (RPE 3-4).

All participants will receive standard care, including dietary advice, general physical activity guidance, and routine antenatal monitoring. The study aims to evaluate the comparative effectiveness of these two exercise modalities on blood glucose levels, exercise tolerance, body weight, and gestational psychological stress.

Outcome measures will be assessed at baseline and after completion of the intervention period. The study will be conducted in a clinical setting using standardized protocols to ensure consistency, safety, and intervention fidelity. This research aims to provide evidence for selecting appropriate, safe, and effective exercise modalities for women with gestational diabetes, particularly in resource-limited settings.

02

Conditions studied

  • Diabetes During Pregnancy
  • Pregnancy Complications
  • Pregnancy in Diabetes
  • Gestational Diabetes Mellitus (GDM)
  • Diabetes Complication
  • Gestational

Keywords

  • gestational diabetes
  • diabetes in pregnancy
  • GDM
  • Gestational
03

In context

Diabetes, Gestational

877 studies on the registry are indexed under Diabetes, Gestational; 203 are open to participants now.

This study's planned enrollment of 108 is close to the median of 110 across 564 interventional studies indexed under Diabetes, Gestational.

Browse Diabetes, Gestational studies →

Lead sponsor

Lahore University of Biological and Applied Sciences is the lead sponsor of 79 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female participants aged 18-35 years.
  2. Gestational age 14-28 weeks (second trimester).
  3. Singleton pregnancy (confirmed by obstetric record) only to avoid complications of multiple gestation.
  4. Include both primigravida and multigravida (i.e., first or subsequent pregnancy).
  5. Women with first time GDM in pregnancy.
  6. Women with clinical diagnosis of gestational diabetes according to hospital/WHO criteria or hospital diagnostic test.
  7. Blood glucose levels:

    Random capillary glucose \< 200 mg/dL at screening (to exclude overt diabetes)

  8. Blood pressure:

    • Systolic BP \< 140 mmHg and Diastolic BP \< 90 mmHg (no confirmed gestational hypertension).
    • If BP ≥140/90 mmHg, confirm with repeat measurement 4 hours apart; exclude if persistent.
  9. Willingness to participate and provide written .
  10. Medically cleared by obstetrician to participate in moderate aerobic exercise.

Exclusion criteria

Exclusion Criteria:

  1. Previous Cesarean section or medically indicated bed rest.
  2. Known pre-existing diabetes mellitus (Type 1 or Type 2 prior to pregnancy).
  3. Known major obstetric complications (e.g., placenta previa, severe pre- eclampsia).
  4. Patients having multiple/twin/triplet pregnancies.
  5. Known major fetal anomaly.
  6. Anemic women with \< 9 g/dL (excluded to prevent exercise intolerance).
  7. Uncontrolled cardiovascular disease, musculoskeletal, or medical to exercise.
  8. Psychiatric conditions severe enough to hinder .
  9. Any other medical condition that, in the opinion of the obstetrician, makes participation unsafe.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Leg Ergometer

    Leg ergometer is used to assess the blood glucose, exercise tolerance, weight, and psychological stress among gestational diabetic patients

    Other: Leg Ergometer

  • Active comparator
    Arm Ergometer

    Arm ergometer is used to compare with leg ergometer to assess the blood glucose, exercise tolerance, weight, psychological stress among gestational diabetic patients

    Other: Arm Ergometer

Interventions

  • OtherLeg Ergometer

    Participants in this group will perform supervised leg ergometer exercise in addition to standard care. The intervention will last for 8 weeks, with sessions conducted 3 times per week, each lasting 20-30 minutes. Exercise will be performed in a seated position using a cycle ergometer, primarily engaging lower-limb muscle groups. Intensity will be maintained at a moderate level (RPE 3-4) using the Modified Borg Scale and will be progressed gradually based on participant tolerance. Each session will include a brief warm-up and cool-down period. Standard care will include dietary counseling, general physical activity advice, and routine antenatal monitoring. Blood glucose may be checked before and after selected sessions to ensure safety and monitor response to exercise.

    Also known as: Cycle Ergometer, Ergocycle

  • OtherArm Ergometer

    Participants in this group will perform supervised arm ergometer exercise in addition to standard care. The intervention will last for 8 weeks, with sessions conducted 3 times per week, each lasting 20-30 minutes. Exercise will be performed in a seated position using an arm cycle ergometer, primarily engaging upper-limb muscle groups. Intensity will be maintained at a moderate level (RPE 3-4) using the Modified Borg Scale and will be progressed gradually based on participant tolerance. Each session will include a brief warm-up and cool-down period. Standard care will include dietary counseling, general physical activity advice, and routine antenatal monitoring. Blood glucose may be checked before and after selected sessions to ensure safety and monitor response to exercise.

    Also known as: Cycle Ergometer, Ergocycle

06

What researchers measure

Primary outcomes

  1. Exercise Tolerance

    Exercise tolerance will be assessed using the Modified Borg Rate of Perceived Exertion (RPE) Scale (0-10)

    Time frame: 8 weeks

  2. Blood Glucose

    Blood glucose levels will be measured using a capillary finger-stick method with a calibrated glucometer.

    Time frame: 8 weeks

  3. Maternal Body Weight

    Maternal body weight will be measured using a calibrated digital weighing scale, placed on a flat, hard surface to ensure accuracy for monitoring gestational weight gain.

    Time frame: 8 weeks

  4. Gestational Diabetes Stress

    The Gestational Diabetes Stress Scale (GDSS) is a self-reported questionnaire used to measure psychological stress specifically related to gestational diabetes.

    Time frame: 8 Weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — IPD will be shared after the publication of the research.

Supporting information: Study protocol, Informed consent form

Time frame: For 5 years

Access criteria: Researchers, Students, Clinicians, Common People

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Sep 2026, 4 months after the start.

Of 307 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 4 months is below that.

Counting every sponsor, half of 310 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
Apr 28, 2026
StartActual
May 26, 2026
Primary completionEst.
Sep 26, 2026
CompletionEst.
Oct 15, 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07554287
Lead sponsor
Lahore University of Biological and Applied Sciences
Responsible party
Umber Nawaz (Assistant Professor, Lahore University of Biological and Applied Sciences) — Principal investigator
First posted
Apr 28, 2026
Start date
May 26, 2026
Primary completion
Sep 26, 2026 (estimated)
Completion
Oct 15, 2026 (estimated)
Last update
Jun 18, 2026

Study contacts

Umber Nawaz, PhD PT
Contact
umber.nawaz@ubas.edu.pk
+923334888279
Shoaib Waqas, PhD. PT
Contact
shoaib.waqas@ubas.edu.pk
+923024552109
Shoaib Waqas, PhD. PT
study chair · Lahore University of Biological and Applied Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion